Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
McKinsey
McKesson
Mallinckrodt
Dow

Last Updated: October 17, 2019

DrugPatentWatch Database Preview

Par Pharm Inc Company Profile

See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for PAR PHARM INC, and when can generic versions of PAR PHARM INC drugs launch?

PAR PHARM INC has thirty-six approved drugs.

There is one US patent protecting PAR PHARM INC drugs. There are seven tentative approvals on PAR PHARM INC drugs.

There are nine patent family members on PAR PHARM INC drugs in eight countries and forty-nine supplementary protection certificates in twelve countries.

Summary for Par Pharm Inc
International Patents:9
US Patents:1
Tradenames:33
Ingredients:33
NDAs:36

Drugs and US Patents for Par Pharm Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Par Pharm Inc METOCLOPRAMIDE HYDROCHLORIDE metoclopramide hydrochloride TABLET;ORAL 070581-001 Oct 17, 1985 AB RX No No   Start Trial   Start Trial
Par Pharm Inc DEXTROAMP SACCHARATE, AMP ASPARTATE, DETROAMP SULFATE AND AMP SULFATE amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 206159-003 May 31, 2019 AB RX No No   Start Trial   Start Trial
Par Pharm Inc DEXMETHYLPHENIDATE HYDROCHLORIDE dexmethylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 202842-001 Nov 30, 2016 AB RX No No   Start Trial   Start Trial
Par Pharm Inc OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil TABLET;ORAL 206137-001 Oct 26, 2016 AB RX No No   Start Trial   Start Trial
Par Pharm Inc MORPHINE SULFATE morphine sulfate CAPSULE, EXTENDED RELEASE;ORAL 200812-003 Nov 10, 2011 AB RX No No   Start Trial   Start Trial
Par Pharm Inc TRAMADOL HYDROCHLORIDE tramadol hydrochloride TABLET, EXTENDED RELEASE;ORAL 078783-003 Sep 20, 2011 AB1 RX No No   Start Trial   Start Trial
Par Pharm Inc TRAMADOL HYDROCHLORIDE tramadol hydrochloride TABLET, EXTENDED RELEASE;ORAL 078783-001 Nov 13, 2009 AB1 RX No No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Par Pharm Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Par Pharm Inc ACCOLATE zafirlukast TABLET;ORAL 020547-003 Sep 17, 1999 5,583,152   Start Trial
Par Pharm Inc ACCOLATE zafirlukast TABLET;ORAL 020547-001 Sep 26, 1996 5,612,367   Start Trial
Par Pharm Inc ACCOLATE zafirlukast TABLET;ORAL 020547-003 Sep 17, 1999 4,859,692   Start Trial
Par Pharm Inc ACCOLATE zafirlukast TABLET;ORAL 020547-001 Sep 26, 1996 4,859,692   Start Trial
Par Pharm Inc ACCOLATE zafirlukast TABLET;ORAL 020547-001 Sep 26, 1996 6,143,775   Start Trial
Par Pharm Inc ACCOLATE zafirlukast TABLET;ORAL 020547-001 Sep 26, 1996 5,294,636   Start Trial
Par Pharm Inc ACCOLATE zafirlukast TABLET;ORAL 020547-003 Sep 17, 1999 5,319,097   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for PAR PHARM INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 10 mg and 20 mg ➤ Subscribe 2008-02-29

Supplementary Protection Certificates for Par Pharm Inc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0502314 SPC/GB11/010 United Kingdom   Start Trial PRODUCT NAME: THE COMBINATION OF A) TELMISARTAN, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALTS, AND B) AMLODIPINE, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALTS, ESPECIALLY AMLODIPINE BESYLATE; REGISTERED: UK EU/1/10/648/001 20101007; UK EU/1/10/648/002 20101007; UK EU/1/10/648/003 20101007; UK EU/1/10/648/004 20101007; UK EU/1/10/648/005 20101007; UK EU/1/10/648/006 20101007; UK EU/1/10/648/007 20101007; UK EU/1/10/648/008 20101007; UK EU/1/10/648/009 20101007; UK EU/1/10/648/010 20101007; UK EU/1/10/648/011 20101007; UK EU/1/10/648/012 20101007; UK EU/1/10/648/013 20101007; UK EU/1/10/648/014 20101007; UK EU/1/10/648/015 20101007; UK EU/1/10/648/016 20101007; UK
0245997 SPC/GB00/005 United Kingdom   Start Trial PRODUCT NAME: DOFETILIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/99/121/001 19991129; UK EU/1/99/121/002 19991129; UK EU/1/99/121/003 19991129; UK EU/1/99/121/004 19991129; UK EU/1/99/121/005 19991129; UK EU/1/99/121/006 19991129; UK EU/1/99/121/007 19991129; UK EU/1/99/121/008 19991129; UK EU/1/99/121/009 19991129; UK EU/1/99/121/010 19991129; UK EU/1/99/121/011 19991129; UK EU/1/99/121/012 19991129; UK EU/1/99/121/013 19991129; UK EU/1/99/121/014 19991129; UK EU/1/99/121/015 19991129
1915993 C300625 Netherlands   Start Trial PRODUCT NAME: COMBINATIE BEVATTENDE ALISKIREN, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE, OF EEN FARMACEUATISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110414
2101777 93081 Luxembourg   Start Trial PRODUCT NAME: AMBRISENTAN UTILISE EN TRAITEMENT COMBINE AVEC TADALAFIL; FRIST REGISTRATION: 20151125
2101777 300813 Netherlands   Start Trial PRODUCT NAME: AMBRISENTAN TOEGEPAST IN COMBINATIEBEHANDELING MET TADALAFIL; REGISTRATION NO/DATE: EU/1/08/451 (C(2008) 1637) 20151125
0199543 97C0031 Belgium   Start Trial PRODUCT NAME: ZAFIRLUKAST; NAT. REGISTRATION NO/DATE: 624 S 295 F 3 19961216; FIRST REGISTRATION: IE PA 51/67/1 19960103
1507558 2012/018 Ireland   Start Trial PRODUCT NAME: ALISKIREN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AMLODIPINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND HYDROCHLOROTHIAZIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; NAT REGISTRATION NO/DATE: EU/1/11/730/001-060 20111122; FIRST REGISTRATION NO/DATE: SWITZERLAND 6167801-6167805 20110705
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Johnson and Johnson
McKesson
Medtronic
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.